- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
According to this study, over the next five years the Oral Hypoglycemic Agents (OHAs) market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Oral Hypoglycemic Agents (OHAs) business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Hypoglycemic Agents (OHAs) market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Oral Hypoglycemic Agents (OHAs), covering the supply chain analysis, impact assessment to the Oral Hypoglycemic Agents (OHAs) market size growth rate in several scenarios, and the measures to be undertaken by Oral Hypoglycemic Agents (OHAs) companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Sulfonylureas
Metformin
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Pfizer
Double-Crane Pharmaceutical
GlaxoSmithKline
Bristol-Myers Squibb
Novonordisk
Bayer
Huadong Medicine
Sanofi-Aventis
Wanbang Biopharmaceuticals
Servier
Guangzhou Pharmaceutical
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Oral Hypoglycemic Agents (OHAs) consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Oral Hypoglycemic Agents (OHAs) market by identifying its various subsegments.
Focuses on the key global Oral Hypoglycemic Agents (OHAs) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Oral Hypoglycemic Agents (OHAs) with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Oral Hypoglycemic Agents (OHAs) submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Hypoglycemic Agents (OHAs) Consumption 2015-2025
2.1.2 Oral Hypoglycemic Agents (OHAs) Consumption CAGR by Region
2.2 Oral Hypoglycemic Agents (OHAs) Segment by Type
2.2.1 Sulfonylureas
2.2.2 Metformin
2.2.3 Thiazolidinediones
2.2.4 Alpha-Glucosidase Inhibitors
2.3 Oral Hypoglycemic Agents (OHAs) Consumption by Type
2.3.1 Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
2.3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue and Market Share by Type (2015-2020)
2.3.3 Global Oral Hypoglycemic Agents (OHAs) Sale Price by Type (2015-2020)
2.4 Oral Hypoglycemic Agents (OHAs) Segment by Application
2.4.1 Type 2 Diabetes Mellitus
2.4.2 Type 1 Diabetes Mellitus
2.5 Oral Hypoglycemic Agents (OHAs) Consumption by Application
2.5.1 Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
2.5.2 Global Oral Hypoglycemic Agents (OHAs) Value and Market Share by Type (2015-2020)
2.5.3 Global Oral Hypoglycemic Agents (OHAs) Sale Price by Type (2015-2020)
3 Global Oral Hypoglycemic Agents (OHAs) by Company
3.1 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Company
3.1.1 Global Oral Hypoglycemic Agents (OHAs) Sales by Company (2018-2020)
3.1.2 Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Company (2018-2020)
3.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Company
3.2.1 Global Oral Hypoglycemic Agents (OHAs) Revenue by Company (2018-2020)
3.2.2 Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Company (2018-2020)
3.3 Global Oral Hypoglycemic Agents (OHAs) Sale Price by Company
3.4 Global Oral Hypoglycemic Agents (OHAs) Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Oral Hypoglycemic Agents (OHAs) Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Oral Hypoglycemic Agents (OHAs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Oral Hypoglycemic Agents (OHAs) by Regions
4.1 Oral Hypoglycemic Agents (OHAs) by Regions
4.2 Americas Oral Hypoglycemic Agents (OHAs) Consumption Growth
4.3 APAC Oral Hypoglycemic Agents (OHAs) Consumption Growth
4.4 Europe Oral Hypoglycemic Agents (OHAs) Consumption Growth
4.5 Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Growth
5 Americas
5.1 Americas Oral Hypoglycemic Agents (OHAs) Consumption by Countries
5.1.1 Americas Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020)
5.1.2 Americas Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020)
5.2 Americas Oral Hypoglycemic Agents (OHAs) Consumption by Type
5.3 Americas Oral Hypoglycemic Agents (OHAs) Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Oral Hypoglycemic Agents (OHAs) Consumption by Regions
6.1.1 APAC Oral Hypoglycemic Agents (OHAs) Consumption by Regions (2015-2020)
6.1.2 APAC Oral Hypoglycemic Agents (OHAs) Value by Regions (2015-2020)
6.2 APAC Oral Hypoglycemic Agents (OHAs) Consumption by Type
6.3 APAC Oral Hypoglycemic Agents (OHAs) Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Oral Hypoglycemic Agents (OHAs) by Countries
7.1.1 Europe Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020)
7.1.2 Europe Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020)
7.2 Europe Oral Hypoglycemic Agents (OHAs) Consumption by Type
7.3 Europe Oral Hypoglycemic Agents (OHAs) Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Oral Hypoglycemic Agents (OHAs) by Countries
8.1.1 Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020)
8.2 Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Type
8.3 Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Oral Hypoglycemic Agents (OHAs) Distributors
10.3 Oral Hypoglycemic Agents (OHAs) Customer
11 Global Oral Hypoglycemic Agents (OHAs) Market Forecast
11.1 Global Oral Hypoglycemic Agents (OHAs) Consumption Forecast (2021-2025)
11.2 Global Oral Hypoglycemic Agents (OHAs) Forecast by Regions
11.2.1 Global Oral Hypoglycemic Agents (OHAs) Forecast by Regions (2021-2025)
11.2.2 Global Oral Hypoglycemic Agents (OHAs) Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Oral Hypoglycemic Agents (OHAs) Forecast by Type
11.8 Global Oral Hypoglycemic Agents (OHAs) Forecast by Application
12 Key Players Analysis
12.1 Pfizer
12.1.1 Company Information
12.1.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.1.3 Pfizer Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Pfizer Latest Developments
12.2 Double-Crane Pharmaceutical
12.2.1 Company Information
12.2.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.2.3 Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Double-Crane Pharmaceutical Latest Developments
12.3 GlaxoSmithKline
12.3.1 Company Information
12.3.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.3.3 GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GlaxoSmithKline Latest Developments
12.4 Bristol-Myers Squibb
12.4.1 Company Information
12.4.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.4.3 Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Bristol-Myers Squibb Latest Developments
12.5 Novonordisk
12.5.1 Company Information
12.5.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.5.3 Novonordisk Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Novonordisk Latest Developments
12.6 Bayer
12.6.1 Company Information
12.6.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.6.3 Bayer Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Bayer Latest Developments
12.7 Huadong Medicine
12.7.1 Company Information
12.7.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.7.3 Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Huadong Medicine Latest Developments
12.8 Sanofi-Aventis
12.8.1 Company Information
12.8.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.8.3 Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Sanofi-Aventis Latest Developments
12.9 Wanbang Biopharmaceuticals
12.9.1 Company Information
12.9.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.9.3 Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Wanbang Biopharmaceuticals Latest Developments
12.10 Servier
12.10.1 Company Information
12.10.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.10.3 Servier Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Servier Latest Developments
12.11 Guangzhou Pharmaceutical
12.11.1 Company Information
12.11.2 Oral Hypoglycemic Agents (OHAs) Product Offered
12.11.3 Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Guangzhou Pharmaceutical Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Oral Hypoglycemic Agents (OHAs) Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Sulfonylureas
Table 5. Major Players of Metformin
Table 6. Major Players of Thiazolidinediones
Table 7. Major Players of Alpha-Glucosidase Inhibitors
Table 8. Global Consumption Sales by Type (2015-2020)
Table 9. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Table 10. Global Oral Hypoglycemic Agents (OHAs) Revenue by Type (2015-2020) ($ million)
Table 11. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Type (2015-2020) ($ Millions)
Table 12. Global Oral Hypoglycemic Agents (OHAs) Sale Price by Type (2015-2020)
Table 13. Global Consumption Sales by Application (2015-2020)
Table 14. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Table 15. Global Oral Hypoglycemic Agents (OHAs) Value by Application (2015-2020)
Table 16. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Application (2015-2020)
Table 17. Global Oral Hypoglycemic Agents (OHAs) Sale Price by Application (2015-2020)
Table 18. Global Oral Hypoglycemic Agents (OHAs) Sales by Company (2017-2019) (K MT)
Table 19. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Company (2017-2019)
Table 20. Global Oral Hypoglycemic Agents (OHAs) Revenue by Company (2017-2019) ($ Millions)
Table 21. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Company (2017-2019)
Table 22. Global Oral Hypoglycemic Agents (OHAs) Sale Price by Company (2017-2019)
Table 23. Global Oral Hypoglycemic Agents (OHAs) Manufacturing Base Distribution and Sales Area by Manufacturers
Table 24. Players Oral Hypoglycemic Agents (OHAs) Products Offered
Table 25. Oral Hypoglycemic Agents (OHAs) Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 26. Global Oral Hypoglycemic Agents (OHAs) Consumption by Regions 2015-2020 (K MT)
Table 27. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Regions 2015-2020
Table 28. Global Oral Hypoglycemic Agents (OHAs) Value by Regions 2015-2020 ($ Millions)
Table 29. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Regions 2015-2020
Table 30. Americas Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020) (K MT)
Table 31. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries (2015-2020)
Table 32. Americas Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020) ($ Millions)
Table 33. Americas Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries (2015-2020)
Table 34. Americas Oral Hypoglycemic Agents (OHAs) Consumption by Type (2015-2020) (K MT)
Table 35. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Table 36. Americas Oral Hypoglycemic Agents (OHAs) Consumption by Application (2015-2020) (K MT)
Table 37. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Table 38. APAC Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020) (K MT)
Table 39. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries (2015-2020)
Table 40. APAC Oral Hypoglycemic Agents (OHAs) Value by Regions (2015-2020) ($ Millions)
Table 41. APAC Oral Hypoglycemic Agents (OHAs) Value Market Share by Regions (2015-2020)
Table 42. APAC Oral Hypoglycemic Agents (OHAs) Consumption by Type (2015-2020) (K MT)
Table 43. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Table 44. APAC Oral Hypoglycemic Agents (OHAs) Consumption by Application (2015-2020) (K MT)
Table 45. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Table 46. Europe Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020) (K MT)
Table 47. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries (2015-2020)
Table 48. Europe Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020) ($ Millions)
Table 49. Europe Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries (2015-2020)
Table 50. Europe Oral Hypoglycemic Agents (OHAs) Consumption by Type (2015-2020) (K MT)
Table 51. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Table 52. Europe Oral Hypoglycemic Agents (OHAs) Consumption by Application (2015-2020) (K MT)
Table 53. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Table 54. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Countries (2015-2020) (K MT)
Table 55. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value by Countries (2015-2020) ($ Millions)
Table 57. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Type (2015-2020) (K MT)
Table 59. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Table 60. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption by Application (2015-2020) (K MT)
Table 61. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Table 62. Oral Hypoglycemic Agents (OHAs) Distributors List
Table 63. Oral Hypoglycemic Agents (OHAs) Customer List
Table 64. Global Oral Hypoglycemic Agents (OHAs) Consumption Forecast by Countries (2021-2025) (K MT)
Table 65. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Forecast by Regions
Table 66. Global Oral Hypoglycemic Agents (OHAs) Value Forecast by Countries (2021-2025) ($ Millions)
Table 67. Global Oral Hypoglycemic Agents (OHAs) Value Market Share Forecast by Regions
Table 68. Global Oral Hypoglycemic Agents (OHAs) Consumption Forecast by Type (2021-2025) (K MT)
Table 69. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share Forecast by Type (2021-2025)
Table 70. Global Oral Hypoglycemic Agents (OHAs) Value Forecast by Type (2021-2025) ($ Millions)
Table 71. Global Oral Hypoglycemic Agents (OHAs) Value Market Share Forecast by Type (2021-2025)
Table 72. Global Oral Hypoglycemic Agents (OHAs) Consumption Forecast by Application (2021-2025) (K MT)
Table 73. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share Forecast by Application (2021-2025)
Table 74. Global Oral Hypoglycemic Agents (OHAs) Value Forecast by Application (2021-2025) ($ Millions)
Table 75. Global Oral Hypoglycemic Agents (OHAs) Value Market Share Forecast by Application (2021-2025)
Table 76. Pfizer Product Offered
Table 77. Pfizer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 78. Pfizer Main Business
Table 79. Pfizer Latest Developments
Table 80. Pfizer Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 81. Double-Crane Pharmaceutical Product Offered
Table 82. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 83. Double-Crane Pharmaceutical Main Business
Table 84. Double-Crane Pharmaceutical Latest Developments
Table 85. Double-Crane Pharmaceutical Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 86. GlaxoSmithKline Product Offered
Table 87. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 88. GlaxoSmithKline Main Business
Table 89. GlaxoSmithKline Latest Developments
Table 90. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 91. Bristol-Myers Squibb Product Offered
Table 92. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 93. Bristol-Myers Squibb Main Business
Table 94. Bristol-Myers Squibb Latest Developments
Table 95. Bristol-Myers Squibb Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 96. Novonordisk Product Offered
Table 97. Novonordisk Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 98. Novonordisk Main Business
Table 99. Novonordisk Latest Developments
Table 100. Novonordisk Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 101. Bayer Product Offered
Table 102. Bayer Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 103. Bayer Main Business
Table 104. Bayer Latest Developments
Table 105. Bayer Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 106. Huadong Medicine Product Offered
Table 107. Huadong Medicine Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 108. Huadong Medicine Main Business
Table 109. Huadong Medicine Latest Developments
Table 110. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 111. Sanofi-Aventis Product Offered
Table 112. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 113. Sanofi-Aventis Main Business
Table 114. Sanofi-Aventis Latest Developments
Table 115. Sanofi-Aventis Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 116. Wanbang Biopharmaceuticals Product Offered
Table 117. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 118. Wanbang Biopharmaceuticals Main Business
Table 119. Wanbang Biopharmaceuticals Latest Developments
Table 120. Wanbang Biopharmaceuticals Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 121. Servier Product Offered
Table 122. Servier Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 123. Servier Main Business
Table 124. Servier Latest Developments
Table 125. Servier Basic Information, Company Total Revenue (in $ million), Oral Hypoglycemic Agents (OHAs) Manufacturing Base, Sales Area and Its Competitors
Table 126. Guangzhou Pharmaceutical Product Offered
Table 127. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 128. Guangzhou Pharmaceutical Main Business
Table 129. Guangzhou Pharmaceutical Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 130. Guangzhou Pharmaceutical Latest Developments
List of Figures
Figure 1. Picture of Oral Hypoglycemic Agents (OHAs)
Figure 2. Oral Hypoglycemic Agents (OHAs) Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Oral Hypoglycemic Agents (OHAs) Consumption Growth Rate 2015-2025 (K MT)
Figure 5. Global Oral Hypoglycemic Agents (OHAs) Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Sulfonylureas
Figure 7. Product Picture of Metformin
Figure 8. Product Picture of Thiazolidinediones
Figure 9. Product Picture of Alpha-Glucosidase Inhibitors
Figure 10. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type (2015-2020)
Figure 11. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Type (2015-2020)
Figure 12. Oral Hypoglycemic Agents (OHAs) Consumed in Type 2 Diabetes Mellitus
Figure 13. Global Oral Hypoglycemic Agents (OHAs) Market: Type 2 Diabetes Mellitus (2015-2020) (K MT)
Figure 14. Global Oral Hypoglycemic Agents (OHAs) Market: Type 2 Diabetes Mellitus (2015-2020) ($ Millions)
Figure 15. Oral Hypoglycemic Agents (OHAs) Consumed in Type 1 Diabetes Mellitus
Figure 16. Global Oral Hypoglycemic Agents (OHAs) Market: Type 1 Diabetes Mellitus (2015-2020) (K MT)
Figure 17. Global Oral Hypoglycemic Agents (OHAs) Market: Type 1 Diabetes Mellitus (2015-2020) ($ Millions)
Figure 18. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application (2015-2020)
Figure 19. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Application (2015-2020)
Figure 20. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Company in 2017
Figure 21. Global Oral Hypoglycemic Agents (OHAs) Sales Market Share by Company in 2019
Figure 22. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Company in 2017
Figure 23. Global Oral Hypoglycemic Agents (OHAs) Revenue Market Share by Company in 2019
Figure 24. Global Oral Hypoglycemic Agents (OHAs) Sale Price by Company in 2019
Figure 25. Global Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Regions 2015-2020
Figure 26. Global Oral Hypoglycemic Agents (OHAs) Value Market Share by Regions 2015-2020
Figure 27. Americas Oral Hypoglycemic Agents (OHAs) Consumption 2015-2020 (K MT)
Figure 28. Americas Oral Hypoglycemic Agents (OHAs) Value 2015-2020 ($ Millions)
Figure 29. APAC Oral Hypoglycemic Agents (OHAs) Consumption 2015-2020 (K MT)
Figure 30. APAC Oral Hypoglycemic Agents (OHAs) Value 2015-2020 ($ Millions)
Figure 31. Europe Oral Hypoglycemic Agents (OHAs) Consumption 2015-2020 (K MT)
Figure 32. Europe Oral Hypoglycemic Agents (OHAs) Value 2015-2020 ($ Millions)
Figure 33. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption 2015-2020 (K MT)
Figure 34. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value 2015-2020 ($ Millions)
Figure 35. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries in 2019
Figure 36. Americas Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries in 2019
Figure 37. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type in 2019
Figure 38. Americas Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application in 2019
Figure 39. United States Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 40. United States Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 41. Canada Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 42. Canada Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 43. Mexico Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 44. Mexico Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 45. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries in 2019
Figure 46. APAC Oral Hypoglycemic Agents (OHAs) Value Market Share by Regions in 2019
Figure 47. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type in 2019
Figure 48. APAC Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application in 2019
Figure 49. China Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 50. China Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 51. Japan Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 52. Japan Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 53. Korea Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 54. Korea Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 55. Southeast Asia Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 56. Southeast Asia Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 57. India Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 58. India Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 59. Australia Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 60. Australia Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 61. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries in 2019
Figure 62. Europe Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries in 2019
Figure 63. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type in 2019
Figure 64. Europe Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application in 2019
Figure 65. Germany Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 66. Germany Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 67. France Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 68. France Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 69. UK Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 70. UK Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 71. Italy Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 72. Italy Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 73. Russia Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 74. Russia Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 75. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Countries in 2019
Figure 76. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value Market Share by Countries in 2019
Figure 77. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Type in 2019
Figure 78. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption Market Share by Application in 2019
Figure 79. Egypt Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 80. Egypt Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 81. South Africa Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 82. South Africa Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 83. Israel Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 84. Israel Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 85. Turkey Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 86. Turkey Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 87. GCC Countries Oral Hypoglycemic Agents (OHAs) Consumption Growth 2015-2020 (K MT)
Figure 88. GCC Countries Oral Hypoglycemic Agents (OHAs) Value Growth 2015-2020 ($ Millions)
Figure 89. Global Oral Hypoglycemic Agents (OHAs) Consumption Growth Rate Forecast (2021-2025) (K MT)
Figure 90. Global Oral Hypoglycemic Agents (OHAs) Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 91. Americas Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 92. Americas Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 93. APAC Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 94. APAC Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 95. Europe Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 96. Europe Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 97. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 98. Middle East & Africa Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 99. United States Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 100. United States Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 101. Canada Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 102. Canada Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 103. Mexico Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 104. Mexico Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 105. Brazil Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 106. Brazil Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 107. China Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 108. China Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 109. Japan Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 110. Japan Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 111. Korea Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 112. Korea Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 113. Southeast Asia Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 114. Southeast Asia Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 115. India Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 116. India Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 117. Australia Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 118. Australia Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 119. Germany Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 120. Germany Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 121. France Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 122. France Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 123. UK Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 124. UK Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 125. Italy Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 126. Italy Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 127. Russia Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 128. Russia Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 129. Spain Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 130. Spain Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 131. Egypt Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 132. Egypt Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 133. South Africa Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 134. South Africa Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 135. Israel Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 136. Israel Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 137. Turkey Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 138. Turkey Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 139. GCC Countries Oral Hypoglycemic Agents (OHAs) Consumption 2021-2025 (K MT)
Figure 140. GCC Countries Oral Hypoglycemic Agents (OHAs) Value 2021-2025 ($ Millions)
Figure 141. Pfizer Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 142. Double-Crane Pharmaceutical Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 143. GlaxoSmithKline Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 144. Bristol-Myers Squibb Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 145. Novonordisk Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 146. Bayer Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 147. Huadong Medicine Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 148. Sanofi-Aventis Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 149. Wanbang Biopharmaceuticals Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 150. Servier Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Figure 151. Guangzhou Pharmaceutical Oral Hypoglycemic Agents (OHAs) Market Share (2018-2020)
Please feel free to write an email to us or to use our electronic ticketing system.
